Last Updated: June 24, 2026

Claims for Patent: 12,582,620

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 12,582,620

Title:	Oral solutions comprising lisdexamfetamine salts
Abstract:	Oral pharmaceutical solution comprising a pharmaceutically acceptable salt of lisdexamfetamine, and a pharmaceutically acceptable aqueous carrier comprising a buffer and a cosolvent selected from the group consisting of a glycol, a polyol, and a mixture thereof, wherein the pH of the solution is from 5.5 to 9.0. The oral pharmaceutical solution presents excellent physicochemical stability, even under alkaline conditions.
Inventor(s):	Georgios LIOLIOS, Ioannis Psarrakis
Assignee:	Adalvo Ltd
Application Number:	US18/167,634
Patent Claims:	1. An oral pharmaceutical solution comprising 10 mg/ml of lisdexamfetamine dimesylate and a pharmaceutically acceptable aqueous carrier comprising a buffer and a cosolvent, wherein the pH of the solution is from 6.0 to 9.0 and wherein the cosolvent comprises a glycol. 2. The oral pharmaceutical solution according to claim 1, wherein the cosolvent comprises propylene glycol, low molecular weight polyethylene glycol, or a mixture thereof and wherein the total concentration of the cosolvent is from 5 mg/ml to 300 mg/ml. 3. The oral pharmaceutical solution according to claim 1, wherein the cosolvent comprises low molecular weight polyethylene glycol. 4. The oral pharmaceutical solution according to claim 1, wherein the total concentration of the cosolvent is from 5 mg/ml to 300 mg/ml. 5. The oral pharmaceutical solution according to claim 1, wherein the total concentration of the cosolvent is from 50 mg/ml to 250 mg/ml. 6. The oral pharmaceutical solution according to claim 1, wherein the total concentration of the cosolvent is from 100 mg/ml to 200 mg/ml. 7. The oral pharmaceutical solution according to claim 1, wherein the pH of the solution is from 6.0 to 8.5. 8. The oral pharmaceutical solution according to claim 1, wherein the pH of the solution is from 6.5 to 8.0. 9. The oral pharmaceutical solution according to claim 1, wherein the cosolvent comprises propylene glycol. 10. The oral pharmaceutical solution according to claim 1, wherein the cosolvent further comprises glycerol, sorbitol, or xylitol. 11. The oral pharmaceutical solution according to claim 7, wherein the cosolvent comprises low molecular weight polyethylene glycol. 12. The oral pharmaceutical solution according to claim 7, wherein the cosolvent comprises propylene glycol. 13. The oral pharmaceutical solution according to claim 7, wherein the cosolvent further comprises glycerol, sorbitol, or xylitol. 14. The oral pharmaceutical solution according to claim 1, wherein the buffer comprises ascorbic acid, acetic acid, tartaric acid, citric acid monohydrate, sodium citrate, potassium citrate, acetic acid, sodium acetate, sodium hydrogen phosphate, sodium dihydrogen phosphate, calcium hydrogen phosphate, calcium dihydrogen phosphate or mixtures thereof. 15. The oral pharmaceutical solution according to claim 1, wherein the buffer comprises a phosphate buffer solution. 16. The oral pharmaceutical solution according to claim 7, wherein the buffer comprises ascorbic acid, acetic acid, tartaric acid, citric acid monohydrate, sodium citrate, potassium citrate, acetic acid, sodium acetate, sodium hydrogen phosphate, sodium dihydrogen phosphate, calcium hydrogen phosphate, calcium dihydrogen phosphate or mixtures thereof. 17. The oral pharmaceutical solution according to claim 7, wherein the buffer comprises a phosphate buffer solution. 18. The oral pharmaceutical solution according to claim 12, wherein the buffer comprises ascorbic acid, acetic acid, tartaric acid, citric acid monohydrate, sodium citrate, potassium citrate, acetic acid, sodium acetate, sodium hydrogen phosphate, sodium dihydrogen phosphate, calcium hydrogen phosphate, calcium dihydrogen phosphate or mixtures thereof. 19. The oral pharmaceutical solution according to claim 12, wherein the buffer comprises a phosphate buffer solution. 20. The oral pharmaceutical solution according to claim 15, wherein the solution further comprises an antimicrobial preservative.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.